News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,302 Results
Type
Article (14227)
Company Profile (282)
Press Release (252793)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79517)
Career Advice (153)
Deals (13225)
Drug Delivery (35)
Drug Development (50454)
Employer Resources (31)
FDA (5721)
Job Trends (5131)
News (144412)
Policy (10031)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (914)
Accelerated approval (2)
Adcomms (12)
Allergies (51)
Alliances (21655)
ALS (63)
Alzheimer's disease (842)
Antibody-drug conjugate (ADC) (89)
Approvals (5741)
Artificial intelligence (119)
Autoimmune disease (17)
Automation (5)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (42)
Biotechnology (232)
Bladder cancer (47)
Brain cancer (20)
Breast cancer (146)
Cancer (1364)
Cardiovascular disease (116)
Career advice (133)
Career pathing (2)
CAR-T (110)
Cell therapy (314)
Cervical cancer (8)
Clinical research (40985)
Collaboration (518)
Compensation (253)
Complete response letters (13)
COVID-19 (1034)
CRISPR (39)
C-suite (154)
Cystic fibrosis (76)
Data (1424)
Denatured (11)
Depression (29)
Diabetes (130)
Diagnostics (1294)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (82)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (88)
Earnings (29738)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48296)
Executive appointments (440)
FDA (6385)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (485)
Gene editing (93)
Generative AI (10)
Gene therapy (240)
GLP-1 (363)
Government (1078)
Grass and pollen (2)
Guidances (19)
Healthcare (6593)
Huntington's disease (22)
IgA nephropathy (22)
Immunology and inflammation (88)
Indications (18)
Infectious disease (1099)
Inflammatory bowel disease (111)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (62)
Interviews (17)
IPO (7267)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (5)
Layoffs (205)
Leadership (3)
Legal (1386)
Liver cancer (31)
Lung cancer (194)
Lymphoma (89)
Machine learning (2)
Management (7)
Manufacturing (126)
MASH (50)
Medical device (2593)
Medtech (2594)
Mergers & acquisitions (6277)
Metabolic disorders (376)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (63)
Neuropsychiatric disorders (23)
Neuroscience (1233)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1627)
Now hiring (22)
Obesity (191)
Opinion (102)
Ovarian cancer (61)
Pain (41)
Pancreatic cancer (53)
Parkinson's disease (119)
Partnered (8)
Patents (123)
Patient recruitment (69)
Peanut (35)
People (25591)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14476)
Phase II (19066)
Phase III (12055)
Pipeline (775)
Policy (43)
Postmarket research (852)
Preclinical (6079)
Press Release (30)
Prostate cancer (57)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (286)
Real estate (1418)
Recruiting (12)
Regulatory (8601)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (57)
Series A (95)
Series B (60)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1431)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1972)
State (1)
Stomach cancer (4)
Supply chain (20)
Tariffs (5)
The Weekly (36)
United States (12675)
Vaccines (208)
Venture capitalists (30)
Weight loss (108)
Women's health (15)
Worklife (2)
Date
Last 7 days (256)
Last 30 days (1287)
Last 365 days (19531)
2025 (5480)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (41)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17251)
Australia (2928)
California (3688)
Canada (1098)
China (332)
Colorado (142)
Connecticut (147)
Delaware (93)
Europe (37127)
Florida (443)
Georgia (115)
Idaho (16)
Illinois (220)
India (10)
Indiana (90)
Iowa (1)
Japan (73)
Kansas (61)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (459)
Massachusetts (2917)
Michigan (70)
Minnesota (142)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (929)
New Mexico (12)
New York (997)
North Carolina (535)
North Dakota (4)
Northern California (1627)
Ohio (109)
Oklahoma (9)
Oregon (21)
Pennsylvania (700)
Puerto Rico (5)
Rhode Island (16)
South America (208)
South Carolina (4)
Southern California (1431)
Tennessee (25)
Texas (423)
Utah (50)
Virginia (74)
Washington D.C. (30)
Washington State (337)
Wisconsin (14)
267,302 Results for "nextpoint therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NextPoint Therapeutics to Highlight Antibody-Drug Conjugate (ADC) and T Cell Engager (TCE) Preclinical Findings Targeting Novel B7-H7 Pathway at AACR Annual Meeting
April 7, 2025
·
2 min read
Genetown
NextPoint Therapeutics Chief Executive Officer Ivan Cheung Named to the 2024 TIME100 Health List
NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7/HHLA2 axis, announced that Chief Executive Officer Ivan Cheung has been named to the 2024 TIME100 Health List.
May 6, 2024
·
2 min read
Business
NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer
NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, today announced the appointment of Ivan Cheung as Chief Executive Officer (CEO) and to the Board of Directors.
February 1, 2024
·
3 min read
Genetown
NextPoint Therapeutics Appoints Tatiana Novobrantseva, PhD, as Chief Scientific Officer
NextPoint Therapeutics, a clinical-stage biotechnology company developing precision immuno-oncology therapeutics targeting the novel HHLA2 pathway, today announced the appointment of Tatiana Novobrantseva, PhD, as Chief Scientific Officer (CSO).
January 16, 2024
·
2 min read
Genetown
NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management
NextPoint Therapeutics announced today the closing of a $42.5M Extension to its Series B financing round resulting in a total of $122.5M raised in the Series B financing.
February 14, 2024
·
3 min read
Press Releases
NextPoint Therapeutics Announces Upcoming Poster Presentation on a B7-H7 Directed T Cell Engager Therapy at SITC2024
November 7, 2024
·
3 min read
Genetown
NextPoint Therapeutics Announces IND Clearance from the FDA to Advance NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
NextPoint Therapeutics today announced the acceptance of its investigational new drug (IND) application by the U.S. Food & Drug Administration (FDA) for NPX887.
December 7, 2023
·
2 min read
Drug Development
NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
NextPoint Therapeutics announced today that the first patient has been dosed with NPX887 in a Phase 1 first-in-human clinical trial for the treatment of patients with solid tumors expressing HHLA2/B7-H7, a tumor antigen strongly upregulated in many human tumors independently of PD-L1.
February 20, 2024
·
2 min read
Business
Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that Axel Hoos, MD, PhD, has joined the NextPoint Board of Directors.
March 21, 2023
·
2 min read
Business
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer
NextPoint Therapeutics announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).
February 21, 2023
·
2 min read
1 of 26,731
Next
